Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Non-Current Liabilities: 2010-2024

Historic Total Non-Current Liabilities for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to -$772,000.

  • Anika Therapeutics' Total Non-Current Liabilities rose 5.58% to -$761,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$761,000, marking a year-over-year increase of 5.58%. This contributed to the annual value of -$772,000 for FY2024, which is 91.09% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Total Non-Current Liabilities is -$772,000, which was down 91.09% from -$404,000 recorded in FY2023.
  • Over the past 5 years, Anika Therapeutics' Total Non-Current Liabilities peaked at -$398,000 during FY2022, and registered a low of -$22.3 million during FY2020.
  • Its 3-year average for Total Non-Current Liabilities is -$524,667, with a median of -$404,000 in 2023.
  • As far as peak fluctuations go, Anika Therapeutics' Total Non-Current Liabilities tumbled by 6,152.10% in 2020, and later spiked by 94.36% in 2021.
  • Anika Therapeutics' Total Non-Current Liabilities (Yearly) stood at -$22.3 million in 2020, then soared by 94.36% to -$1.3 million in 2021, then soared by 68.36% to -$398,000 in 2022, then decreased by 1.51% to -$404,000 in 2023, then tumbled by 91.09% to -$772,000 in 2024.